IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRADEMIN re Application: David W. Morris, et al.

Serial No.: 10/737,318

Group Art Unit: 1645

Filed: 15 December 2003

Examiner: Not yet assigned

For: NOVEL THERAPEUTIC TARGETS IN CANCER

EXPRESS MAIL INFORMATION:

Express Mail Label No. EL 147521302US

Date Of Deposit: 19 April 2005

Mail Stop Missing Parts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

L	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
V	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute compact discs of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute compact discs of the Sequence Listing do not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

CHIR0018-100 (23352.0001)

PATENT

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

m Attwell (Reg. 45,449)

Date: April 19,2005

COZEN O'CONNOR, P.C. 1900 Market Street – 5th Floor Philadelphia, PA 19103-3508 Telephone: (215) 665-2000